Description

CJC-1295 with DAC Peptide for Advanced GHRH Receptor and Neuroendocrine Research.

CJC-1295 with DAC Peptide is a long-acting analog of growth hormone-releasing hormone (GHRH 1-29) designed to provide sustained receptor activation through reversible binding to circulating serum albumin. The peptide incorporates a Drug Affinity Complex (DAC) attached to the C-terminal lysine residue, significantly extending its pharmacokinetic profile compared with native GHRH and short-acting GHRH analogs.

Scientific investigations utilize CJC-1295 with DAC across endocrinology, neuroendocrinology, molecular pharmacology, peptide chemistry, and receptor biology. Laboratory studies commonly examine GHRH receptor activation, pituitary signal transduction, pulsatile endocrine signaling, receptor trafficking, intracellular kinase activation, peptide pharmacokinetics, and hormone regulatory networks.

Researchers also investigate prolonged receptor occupancy, albumin-mediated peptide stabilization, intracellular calcium signaling, cyclic AMP production, transcriptional regulation, and neuroendocrine communication. Its extended duration of receptor availability makes CJC-1295 with DAC an important experimental reagent for studies requiring sustained endocrine signaling under controlled laboratory conditions.

Each batch is synthesized under rigorous quality-controlled manufacturing procedures, analytically verified for purity and sequence integrity, and supplied as a stable lyophilized peptide with a comprehensive Certificate of Analysis to ensure reproducible laboratory investigations.

For research use only. Not intended for human consumption or clinical use.

Key Research Highlights

• Synthetic 30-amino-acid GHRH analog
• Drug Affinity Complex (DAC) enables reversible albumin binding
• Extended pharmacokinetic profile compared with native GHRH
• High affinity for GHRH receptors
• Extensively investigated in neuroendocrine signaling research
• Frequently utilized in pituitary receptor biology studies
• Evaluated in pharmacokinetic and peptide stability investigations
• High-purity lyophilized peptide suitable for laboratory applications
• Certificate of Analysis (COA) supplied with every batch
• Manufactured under stringent analytical quality standards
• Excellent batch-to-batch reproducibility
• Suitable for biotechnology, pharmaceutical, and academic research laboratories

Why Researchers Choose This Product

• ≥99% research-grade purity verified through analytical testing
• Verified DAC-modified GHRH analog sequence
• Extended stability through albumin-binding technology
• Stable lyophilized formulation for laboratory storage
• Comprehensive Certificate of Analysis included
• Reliable reproducibility across experimental investigations
• Suitable for endocrinology and receptor pharmacology research
• Manufactured using rigorous peptide synthesis protocols
• Excellent analytical consistency between production batches
• Intended exclusively for scientific laboratory investigations

Research Applications

GHRH Receptor Biology

CJC-1295 with DAC Peptide is extensively utilized in laboratory investigations examining GHRH receptor activation, receptor pharmacology, ligand binding kinetics, receptor trafficking, and intracellular signaling.

Neuroendocrine Signaling

Researchers employ CJC-1295 with DAC to investigate hypothalamic-pituitary communication, endocrine signaling dynamics, intracellular messenger systems, and neuroendocrine regulatory mechanisms.

Pharmacokinetic Research

Experimental models utilize CJC-1295 with DAC to study albumin binding, peptide distribution, biological persistence, metabolic stability, and receptor occupancy over extended time periods.

Molecular Endocrinology

Scientists investigate cyclic AMP signaling, protein kinase activation, calcium mobilization, transcription factor regulation, and endocrine cell communication.

Receptor Pharmacology

Laboratory investigations examine receptor internalization, signaling duration, ligand affinity, structure-function relationships, and peptide-receptor interactions.

Peptide Chemistry

Researchers utilize CJC-1295 with DAC for analytical characterization, formulation development, stability studies, peptide engineering, and structure-activity relationship investigations.

Product Specifications

Mechanism of Action

CJC-1295 with DAC Peptide is a modified analog of growth hormone-releasing hormone (GHRH) engineered to activate the growth hormone-releasing hormone receptor (GHRHR) while exhibiting an extended pharmacokinetic profile through incorporation of a Drug Affinity Complex (DAC). The DAC moiety forms a reversible covalent interaction with circulating serum albumin, substantially reducing renal clearance and enzymatic degradation compared with native GHRH peptides. This prolonged circulation enables sustained receptor availability in experimental laboratory models.

Upon binding to the GHRH receptor, a Class B G protein-coupled receptor (GPCR) expressed primarily on anterior pituitary somatotroph cells, CJC-1295 with DAC activates the Gs protein–adenylyl cyclase pathway, increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), initiating phosphorylation of downstream signaling proteins and transcription factors involved in endocrine cell function and receptor-mediated signaling.

Published laboratory investigations have also demonstrated activation of additional intracellular pathways, including CREB, MAPK/ERK, calcium-dependent signaling, and transcriptional regulators associated with pituitary hormone synthesis and cellular communication. Researchers utilize these signaling cascades to investigate receptor pharmacology, peptide-mediated signal amplification, and mechanisms regulating endocrine cell responsiveness.

The defining characteristic of CJC-1295 with DAC is its prolonged interaction with serum albumin. Through reversible albumin conjugation, the peptide maintains extended systemic availability in experimental systems, allowing researchers to study sustained GHRH receptor activation, receptor recycling, intracellular signaling kinetics, and long-duration pharmacodynamic responses. This distinguishes CJC-1295 with DAC from shorter-acting GHRH analogs commonly used in laboratory investigations.

Researchers also investigate receptor desensitization, ligand-receptor kinetics, peptide stability, intracellular messenger dynamics, and neuroendocrine pathway regulation using molecular biology, receptor pharmacology, and peptide chemistry techniques. Its defined molecular structure, extended biological persistence, and well-characterized receptor pharmacology make CJC-1295 with DAC Peptide an important research reagent for endocrinology, neuroendocrine biology, molecular pharmacology, biotechnology, and life science laboratories.

For research use only. Not intended for human consumption or clinical use.